TORONTO, Dec. 10, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is excited to announce that it has completed release testing of its first Australian-made batch of LaNeo™ MDMA 40mg capsules. “PharmAla is pleased to have completed this first batch of material of Australian-made materials in partnership with o ...